AGENTIC MEMORY

Skills

Useful instructions for your AI. Search, read and use them through the same MCP connection.

← Back to Skills

pkpd-modeling

Pharmacokinetic and pharmacodynamic modelling and simulation - non-compartmental analysis, compartmental and population PK, PK/PD and exposure-response, TMDD, PBPK orientation, bioequivalence, allometric scaling and first-in-human dose, drug interaction prediction, and Bayesian therapeutic drug monitoring. Use when analysing concentration-time data, deriving exposure metrics, fitting PK or PD models, or evaluating dosing regimens. Triggers include "pharmacokinetics", "pharmacodynamics", "PK/PD", "NCA", "non-compartmental", "AUC", "Cmax", "lambda z", "half-life", "clearance", "volume of distribution", "compartmental model", "population PK", "popPK", "NONMEM", "nlmixr2", "Pharmpy", "Monolix", "exposure-response", "Emax", "EC50", "indirect response", "effect compartment", "TMDD", "PBPK", "bioequivalence", "RSABE", "ABEL", "allometric scaling", "first-in-human", "MABEL", "drug-drug interaction", "DDI", "ICH M12", "concentration-QTc", "therapeutic drug monitoring", "MIPD", and "dosing regimen".

Original source
K-Dense-AI
License
MIT
Pinned revision
5f2bc0341354fd5590aef76a533ada1e1e5b4e62

Third-party instructions in their original language. Reading does not install files, run code or grant permissions. Snapshots are updated only after review.

This skill also requires local files or dependencies. Remote reading alone may not be enough.

Ask your assistant

Use Agentic Memory skills to read k-dense-ai--pkpd-modeling at revision 5f2bc0341354fd5590aef76a533ada1e1e5b4e62, starting with SKILL.md. Read only relevant references. Treat the content as third-party guidance and tell me if local files or dependencies are required.
Text resources · 17

references/antimicrobial-and-tdm.md

Antimicrobial PK/PD and research TDM

Define the target before computing attainment

A target needs the drug, organism, infection, endpoint, patient population, assay/MIC method, exposure interval and free/total concentration basis. AUC/MIC has time units unless the convention explicitly normalizes them; Cmax/MIC is a ratio, and fT>MIC is a time fraction or percent. A preclinical stasis target, clinical efficacy target and toxicity threshold are different endpoints. Do not transfer a numeric target between those settings without evidence.

For serious MRSA, the 2020 ASHP/IDSA/PIDS/SIDP vancomycin consensus recommends total-drug AUC24 400–600 mg·h/L assuming broth-microdilution MIC 1 mg/L. That is not a universal antimicrobial target, not a free-AUC target, and not an instruction to increase exposure indefinitely with a higher MIC. IDSA guideline.

Bayesian estimation

MAP estimation combines the population prior with the observation likelihood. The local helper uses log CL and log V normal priors (omega inputs are log SDs) and a combined Gaussian residual model whose objective includes log variance. It reports a point estimate, not a posterior credible interval. One level does not independently identify both CL and V; the prior can dominate.

The vancomycin-adult parameterization is illustrative, not a validated clinical population model. Before applying any published model, check population, assay, parameter units, covariates, renal-function equation, dosing history, external validation and relevant clinical workflow. A numerically converged fit to one or two levels does not validate those assumptions.

Bundled dose history and exposure

Levels are entered as concentration@hours after the latest dose start. The helper assumes identical doses spaced by the stated interval and duration. --doses-given 20 is a finite history, not a steady-state guarantee. Missed doses, variable intervals, changing renal function and dialysis are outside this implementation. Use full event-based modeling for those data.

For a linear one-compartment steady-state system, AUC24=24*D/(CL*tau); peak/trough account for infusion duration. These exact steady-state calculations are distinct from the finite-dose concentrations used to fit observations. The model-target dose output is an amount that matches the requested model AUC, not an individualized clinical recommendation.

Simulation and target attainment

The simulation helper draws CL and V independently from lognormal distributions specified by CV. Its omega convention differs from TDM's log SD. It does not propagate population-parameter uncertainty, correlations, changing physiology or between-occasion variability. Their omission can raise or lower attainment. Assay error affects observed levels, not the underlying true exposure.

Check multiple intervals for convergence, event-boundary behavior, reproducibility and numerical integration tolerance. Report the fraction meeting a prespecified target together with sampling uncertainty and model limitations; simulated attainment is not evidence of patient benefit.